Despite Positive Data, Can Genocea Build A Market?
This article was originally published in Scrip
Genocea Biosciences is one step closer to moving its lead candidate into Phase III, but despite positive results, there may not be a strong market for the drug. Unlike the buzz around immunotherapies in oncology, Genocea has not been able to harness that excitement for its non-cancer immunotherapy.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.